S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NYSE:RCUS - Arcus Biosciences Stock Price, Forecast & News

$8.81
+0.26 (+3.04 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$8.50
Now: $8.81
$8.94
50-Day Range
$7.31
MA: $8.13
$9.52
52-Week Range
$6.30
Now: $8.81
$13.66
Volume67,400 shs
Average Volume167,254 shs
Market Capitalization$404.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-694-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.35 million
Book Value$5.29 per share

Profitability

Net Income$-49,590,000.00
Net Margins-1,180.37%

Miscellaneous

Employees108
Market Cap$404.02 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive RCUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.


Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences Inc (NYSE:RCUS) announced its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.02. The firm earned $1.75 million during the quarter, compared to the consensus estimate of $1.34 million. Arcus Biosciences had a negative net margin of 1,180.37% and a negative return on equity of 38.73%. View Arcus Biosciences' Earnings History.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Arcus Biosciences.

What price target have analysts set for RCUS?

5 brokerages have issued 1 year price objectives for Arcus Biosciences' stock. Their forecasts range from $15.00 to $22.00. On average, they anticipate Arcus Biosciences' stock price to reach $19.25 in the next year. This suggests a possible upside of 118.5% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.

What is the consensus analysts' recommendation for Arcus Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.

Has Arcus Biosciences been receiving favorable news coverage?

Media stories about RCUS stock have trended somewhat negative recently, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcus Biosciences earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Arcus Biosciences.

Are investors shorting Arcus Biosciences?

Arcus Biosciences saw a drop in short interest during the month of November. As of November 29th, there was short interest totalling 1,390,000 shares, a drop of 12.0% from the November 14th total of 1,580,000 shares. Based on an average daily trading volume, of 231,500 shares, the short-interest ratio is currently 6.0 days. Currently, 5.5% of the company's stock are sold short. View Arcus Biosciences' Current Options Chain.

Who are some of Arcus Biosciences' key competitors?

What other stocks do shareholders of Arcus Biosciences own?

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the folowing people:
  • Dr. Terry Rosen Ph.D., Co-Founder, Chairman & CEO (Age 59)
  • Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)
  • Mr. Steven Chan, Consultant (Age 47)
  • Ms. Rekha Hemrajani, Chief Operating & Financial Officer (Age 49)
  • Dr. Stephen Young Ph.D., VP of Technology (Age 50)

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (1.35%), Millennium Management LLC (0.41%), Parallel Advisors LLC (0.19%), California State Teachers Retirement System (0.11%), Rhumbline Advisers (0.11%) and Barclays PLC (0.05%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.

Which major investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Bailard Inc.. View Insider Buying and Selling for Arcus Biosciences.

Which major investors are buying Arcus Biosciences stock?

RCUS stock was bought by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, Millennium Management LLC, State Street Corp, California Public Employees Retirement System, Russell Investments Group Ltd., Rhumbline Advisers, Meeder Asset Management Inc. and California State Teachers Retirement System. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $8.81.

How big of a company is Arcus Biosciences?

Arcus Biosciences has a market capitalization of $404.02 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is http://www.arcusbio.com/.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]


MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  213
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel